Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. Vollebergh MA, et al. Among authors: de vries ege, de bruin m, van de vijver mj, van beers eh, van tinteren h. Ann Oncol. 2011 Jul;22(7):1561-1570. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6. Ann Oncol. 2011. PMID: 21135055 Free PMC article. Clinical Trial.
p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ. Clahsen PC, et al. Among authors: van den broek l, van de vijver mj, van de velde cj. J Clin Oncol. 1998 Feb;16(2):470-9. doi: 10.1200/JCO.1998.16.2.470. J Clin Oncol. 1998. PMID: 9469330 Clinical Trial.
High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, van de Vijver MJ. Elkhuizen PH, et al. Among authors: van slooten hj, van de vijver mj, van de velde cj, van den broek lc. J Clin Oncol. 2000 Mar;18(5):1075-83. doi: 10.1200/JCO.2000.18.5.1075. J Clin Oncol. 2000. PMID: 10694560 Clinical Trial.
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.
Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ. Bijker N, et al. Among authors: van de vijver mj, de mascarel i. J Clin Oncol. 2001 Apr 15;19(8):2263-71. doi: 10.1200/JCO.2001.19.8.2263. J Clin Oncol. 2001. PMID: 11304780 Clinical Trial.
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers EJ, Richelt DJ, Rodenhuis S. Schrama JG, et al. Among authors: van de vijver mj, van tinteren h. Ann Oncol. 2002 May;13(5):689-98. doi: 10.1093/annonc/mdf203. Ann Oncol. 2002. PMID: 12075736 Free article. Clinical Trial.
A gene-expression signature as a predictor of survival in breast cancer.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. van de Vijver MJ, et al. Among authors: van t veer lj, van der velde t. N Engl J Med. 2002 Dec 19;347(25):1999-2009. doi: 10.1056/NEJMoa021967. N Engl J Med. 2002. PMID: 12490681 Free article.
312 results